Jump to content

Page values for "Budesonide"

"Medicines" values

1 row is stored for this page
FieldField typeValue
genericStringBudesonide
brandStringPulmicort (inhaled), Rhinocort (intranasal), Entocort EC and Uceris (enteric-coated oral for IBD), Symbicort (with formoterol)
structureFile
classesList of String, delimiter: ,[[:Category:Corticosteroids|Corticosteroid]] [[:Category:Glucocorticoids|Glucocorticoid]] [[:Category:Inhaled_corticosteroids|Inhaled corticosteroid (ICS)]]
mechanismString
usesString'"`UNIQ--vote-0000099F-QINU`"', '"`UNIQ--vote-000009A0-QINU`"', '"`UNIQ--vote-000009A1-QINU`"', '"`UNIQ--vote-000009A2-QINU`"', '"`UNIQ--vote-000009A3-QINU`"', '"`UNIQ--vote-000009A4-QINU`"'
starting_doseStringICS Pulmicort Flexhaler 180-360 mcg BID; intranasal Rhinocort 64 mcg/spray, 1-2 sprays/nostril daily; Entocort EC 9 mg PO daily for active Crohn's; Symbicort 80/4.5 or 160/4.5 mcg, 2 puffs BID
preparationsStringPulmicort Flexhaler DPI 90, 180 mcg/dose; Pulmicort Respules 0.25, 0.5, 1 mg/2 mL nebulized; Rhinocort intranasal 32 mcg/spray; Entocort EC 3 mg capsules; Uceris 9 mg ER tablets and rectal foam
fda_maxStringICS ~1280 mcg/d; intranasal 256 mcg/d; Entocort 9 mg/d standard
pill_idText
routesList of String, delimiter: ,Inhaled intranasal oral (enteric-coated rectal foam) nebulized
onsetStringInhaled: bronchial effect 1-2 weeks; oral GI effect 1-2 weeks
durationString12-24 hours
halflifeString~2-3.6 hours (plasma)'"`UNIQ--ref-000009A5-QINU`"'
bioavailabilityString~6-13% inhaled lung deposition; ~10% oral (Entocort EC; extensive first-pass via CYP3A4 — this is the basis of the favorable hepatic-targeted local-effect profile in IBD)'"`UNIQ--ref-000009A6-QINU`"'
pregnancyStringLong the preferred ICS in pregnancy (Pulmicort) due to the most pregnancy data among the class.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup>
legalStringOTC (intranasal Rhinocort Allergy) and [[USLegal:Prescription only|Rx-only]] (other forms) in US